COVID-19 mutations start producing second generation universal vaccines

This is an attempt to stem the momentum of new coronary mutations, which seem to favor higher transmission and serious forms of the disease.

The first vaccines that were produced, which have begun to be administered worldwide, are designed considering the first version of Covid-19, but what is their impact on the mutations of Great Britain and South Africa, for which there is not yet accurate data, writes abcnews. al

Although vaccines developed with m-tech ARN, as are those of Modernna and Pfizer / BioNTech, actually, seems to cover new mutations, AstraZeneca vaccines / Oxford University are less effective against South Africa's mutation.

This raises the question of whether other vaccines, expected to eventually be approved, will fully protect us from the mutant species of the coronary. The struggle to create a new generation of vaccines that will offer universal protection has already begun worldwide. Why, though, does the coronary change?

When SARS-CoV-2 reproduces into human cells, errors in its spread process occur more frequently. Many such mistakes do not have obvious results, but others can lead to changes in its structure and influence how the virus infects humans.

According to Thomas Reidmacher, founder of Britain's Emergex Vaccines vaccines, the more people become infected with the virus, the more mutations happen. Some of these mutations are useful for reproduction of the virus so that it can perpetuate”.

Most vaccines for COVIDD-19 -- currently available or on clinical trials -- train the immune system to detect antigens on the surface of SARS-CoV-2. The most commonly used antigen is protein S, which is considered to be the most effective target for the vaccine. However, mutations in protein S (which took place in the case of British mutations, South Africa and Brazil) are the main reasons for concern.

Universal Vacination

Under the weight of all that was previously said, pharmaceutical companies and the scientific community are already finding ways to develop effective vaccines against COVID-19 mutant posts.

Moderne develops a “strengthening” to better address new versions of SARS-cov-2. AstraZeneca recently said it would take between six and nine months to produce a new vaccine that is effective against new strains. While CureVac in collaboration with GlaxoSmithKline is developing a new generation mARN vaccine, which will operate against a wide range of coronary variants.

The purpose of these new efforts is to create the so-called <x0-universal vaccine”, which will be effective against the constantly changing coronary.